AzTrials
AzTrials

ContraceptionPhase 4NCT02674139

Comparison Between Intrauterine Contraceptive Device Insertion During Cesarean Section Vs Conventional Application

A Phase 4 study testing Copper T 380A IUD in people with Contraception, run by sara AbdAllah.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The study aims to compare immediate post-placental (within 10 minutes of placenta delivery) intrauterine contraceptive device (Copper T 380A) insertion versus conventional placement at 6 weeks (often referred to as delayed or interval insertion) regarding the clinical outcomes (safety, efficacy, expulsion and… Read more about this study

Who is it for?
Ages 18 to 45 years, women onlyHealthy volunteers can take part
Conditions the study is for
Contraception
What is being tested?
Copper T 380A IUD
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
8 participants
Where
No sites listed yet
Study dates
Feb 2016to Jun 2017
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Age: 18 - 45 years.
  • GA 36-40 weeks based upon the date of last normal menstruation, confirmed by ultrasonographic scan.
  • Desire to have intrauterine contraceptive device (Cu T) after counseling about different contraceptive options and consented to the study.

Who cannot join

  • Allergy to copper.
  • Ante- or intra-partum hemorrhage.
  • Hemorrhagic disorders.
  • Current or past history of pelvic inflammatory disease.
  • Women known to have pelvic TB.
  • Known to have ruptured membranes for more than 24 h prior to delivery.
Show all 15Show fewer
  • History of chorioamnionitis.
  • Known uterine abnormalities e.g., Bicornuate/septate Uterus, uterine myoma.
  • Patients presented with febrile morbidity prior to the operation defined as temperature above 38'c.
  • Multiple pregnancies.
  • Placenta previa.
  • History of ectopic pregnancy.
  • Anemia (hemoglobin <10 g/dl).
  • Cervical cancer or carcinoma in situ.
  • Diagnosis of active cervical infection for standard insertion.

About this study

Official title: Comparative Study of Intrauterine Contraceptive Device Insertion During Caesarean Section Versus Conventional Application

The study aims to compare immediate post-placental (within 10 minutes of placenta delivery) intrauterine contraceptive device (Copper T 380A) insertion versus conventional placement at 6 weeks (often referred to as delayed or interval insertion) regarding the clinical outcomes (safety, efficacy, expulsion and continuation rates) for women undergoing caesarean section.

Read the detailed description
  • Study Design: A controlled randomized clinical trial (CRCT)
  • Study Site: The study will be carried out in the Department of Obstetrics and Gynecology at Beni-suef University Hospital
  • Study Population: The study population will include pregnant women between 36-40 weeks gestational ages who attend antenatal care and are eligible for insertion of IUCD during delivery through elective caesarean section.
  • Study Sample: The study will consist of 200 women which will be chosen randomly to whom elective lower segment caesarean section will be done at the Obstetrics and Gynecology department, willing to have an intrauterine device (IUD) inserted for postpartum contraception and willing to comply with the study protocol.

After informed consent is obtained, eligible study participants will be randomized into 2 groups:

Group (A): 100 Women will receive the Pregna ® IUD at the 6 week postpartum visit Group (B): 100 Women will receive the Pregna ® IUD within 10 minutes of delivery of the placenta during caesarean section.

  • Study Procedure:

Insertion Technique:

During caesarean section:

Uterine cavity will be inspected for presence of malformations following placental delivery, which would limit use of IUCD.The IUCD (Pregna Copper T 380A) will be removed from the insertion sleeve and will be placed on the sterile field. Uterus is stabilized by grasping it at fundus. Insertion will be done during cesarean delivery, after ex pulsion of placenta and through the uterine incision, manually (IUCD is Held between middle and index finger). It will be inserted into the uterus through uterine incision and will be released at fundus of uterus. Hand will be removed slowly from the uterus. Enough care will be taken not to dislodge IUCD as hand is removed. Strings will be guided toward the lower uterine segment without disturbing IUCD'S fundal position. Enough Care will be taken not to include IUCD strings during uterine closure.

Delayed postpartum IUDs Will be inserted in the usual sterile fashion as described in the manufacturer's instructions at the 6-week postpartum visit

Later Prior to Discharge:

  • IUCD Client card, showing type of IUCD and date of insertion will be given to patient.
  • She will be informed about the IUCD side effects and normal postpartum symptoms.
  • Patients will be scheduled for a control examination at 1 week, 6 weeks, 3 months and 6 months after the insertion.
  • She will be advised to contact one of the physicians immediately if they experienced:-
  • Unusual vaginal discharge different from the usual lochia.
  • Lower abdominal pain, especially if accompanied by fever or chills.
  • Feeling of being pregnant.
  • Suspicion that the IUCD has fallen out.

Follow up visits:

  • At each visit the patients will be questioned for symptoms of expulsion, excessive bleeding and infection. In addition, a pelvic examination (per speculum) and trans-vaginal ultrasound will be performed at each follow-up visit.
  • In per speculum examination if IUD threads are long, they will be cut 2 cm from external os. If threads of IUD are not seen and there was no history of expulsion of IUD, pelvic ultrasonography or X-ray pelvis will be done to note for misplaced IUD.
  • All the patients will subjected to the follow up:
  • The IUD will be removed in the case of partial expulsion, bleeding or pain, or at the patient's request.
  • Ethical Considerations 1-Approval by the institution ethical committee 2-Individual Consent Process: Written informed consent will be taken after explaining the study objective the procedures to potential participants. Participation will be voluntary and participants will be informed that the decision not to participate will not impact on the quality of care they receive.
  • The statistical Analysis:

Data will be statistically described in terms of mean + standard deviation (+/- SD), frequencies (number of cases) and relative frequencies (percentages) when appropriate. Comparison of numerical variables between the study groups will be done using Student t test for independent samples. For comparing categorical data, Chi square (X2) test will be performed. Exact test will be used instead when the expected frequency is less than 5. P values less than 0.05 will be considered statistically significant.

Conditions
Contraception
Being tested
Copper T 380A IUD
Keywords
post placental-caesarean-IUD

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Copper T 380A IUDDevice

    Also called Pregna

    intrauterine contraceptive device T-shaped loaded with cupper

Study groups in NCT02674139
Study groupRoleWhat they receive
IUD insertion 6 Weeks after deliveryActive comparatorSubjects randomized to interval placement will have their Copper T 380A IUD placed in the office at six weeks postpartum or later
Receives: Device: Copper T 380A IUD
Immediate Post-placental insertionExperimentalSubjects randomized to receive the Copper T 380A IUD within 10 minutes of delivery of the placenta during caesarean section.
Receives: Device: Copper T 380A IUD

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Expulsion: Complete IUD expulsion will be verified clinically and by transvaginal ultrasound

    Complete IUD expulsion will be verified clinically and by transvaginal ultrasound. An IUD will be considered to be partially expelled if a distance greater than 10 mm is measured between the vertical arm of the IUD and the junction between the endometrium and the uterine cavity)

    Measured: 6 months

Secondary outcomes (6)
  1. Uterine perforation (assessed by pelvic ultrasonography or X-ray)

    To be assessed by pelvic ultrasonography or X-ray pelvis will to note for misplaced IUD

    Measured: 6 months

  2. Pelvic pain (using the 0-10 Numeric Pain Rating Scale)

    Using the 0-10 Numeric Pain Rating Scale and analgesic doses required

    Measured: 6 months

  3. Strings not visible (assessed by speculum examination)

    To be assessed by speculum examination.

    Measured: 6 months

  4. Pelvic infection: number of participants with Pelvic infection

    number of participants with Pelvic infection

    Measured: 6 months

  5. Psychological (satisfied or not) using questionnaire

    using questionnaire

    Measured: 6 months

  6. Pregnancy (assessed by serum pregnancy test and pelvic ultrasound)

    To be assessed by serum pregnancy test and pelvic ultrasound in suspicious cases (missed period - misplaced IUD - expelled IUCD either partial or complete)

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Feb 2016 (estimated)
  2. Study startFeb 2016
  3. Primary completionMar 2017 (estimated)
  4. Study completionJun 2017 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
8 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02674139
Sponsor's protocol ID
GO-MD-IUD
Status last verified
Sep 2016
First submitted
30 Jan 2016
Last updated
27 Sep 2016
Results posted
No
Data monitoring committee
Yes
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Copper T 380A IUD in people with Contraception, run by sara AbdAllah.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 27 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Expulsion: Complete IUD expulsion will be verified clinically and by transvaginal ultrasound (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Sep 2016.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in